Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065071 | 0.94 | — | — | |
| SCHEMBL6694810 | 0.67 | — | — | |
| SCHEMBL127850 | 0.66 | HTR6 (0.56) | HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL583879 | 0.66 | HTR6 (0.56) | HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL12070058 | 0.65 | HTR6 (0.38) | HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL17100712 | 0.65 | L3MBTL3 (0.38) | HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL2065720 | 0.65 | HTR6 (0.42) | HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL30909113 | 0.64 | L3MBTL3 (0.36) | HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL24782761 | 0.63 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1 | |
| SCHEMBL21422636 | 0.63 | HTR6 (0.54) | HTR6L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1070711-B1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1352906-A1 | COMPOSITIONS FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Sankyo Company, Limited (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1243589-A1 | Heteroaryl-substituted pyrrole derivates, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-1070711-A2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | HTR6 2513/4885L3MBTL3 4165/4885L3MBTL1 4201/4885 |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | HTR6 2388/4885L3MBTL3 4381/4885L3MBTL1 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.